{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:52:47Z","timestamp":1762980767549},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Oncol Rep"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s11912-019-0841-z","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T05:05:13Z","timestamp":1566623113000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cardiovascular Effects of Androgen Deprivation Therapy in Prostate Cancer"],"prefix":"10.1007","volume":"21","author":[{"given":"Megha","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy","family":"Canan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Glover","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nidhi","family":"Thareja","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andre","family":"Akhondi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua","family":"Rosenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"841_CR1","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/bjc.2017.280","volume":"117","author":"R Haque","year":"2017","unstructured":"Haque R, UlcickasYood M, Xu X, Cassidy-Bushrow AE, Tsai HT, Keating NL, et al. Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. Br J Cancer. 2017;117:1233\u201340.","journal-title":"Br J Cancer"},{"key":"841_CR2","doi-asserted-by":"crossref","first-page":"4448","DOI":"10.1200\/JCO.2006.06.2497","volume":"24","author":"NL Keating","year":"2006","unstructured":"Keating NL, O\u2019Malley AJ, Smith MR. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2006;24:4448\u201356.","journal-title":"Journal of clinical oncology : official journal of the American Society of Clinical Oncology"},{"key":"841_CR3","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1084\/jem.72.6.747","volume":"72","author":"C Huggins","year":"1940","unstructured":"Huggins C, Clark PJ. Quantitative studies of prostatic secretion : ii. The effect of castration and of estrogen injection on the normal and on the hyperplastic prostate glands of dogs. J Exp Med. 1940;72:747\u201362.","journal-title":"J Exp Med"},{"key":"841_CR4","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1200\/JCO.2018.78.0619","volume":"36","author":"MJ Morris","year":"2018","unstructured":"Morris MJ, Rumble RB, Basch E, Hotte SJ, Loblaw A, Rathkopf D, et al. Optimizing anticancer therapy in metastatic non-castrate prostate cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36:1521\u201339.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"841_CR5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1097\/00005392-200204000-00021","volume":"167","author":"J Trachtenberg","year":"2002","unstructured":"Trachtenberg J, Gittleman M, Steidle C, Barzell W, Friedel W, Pessis D, et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. J Urol. 2002;167:1670\u20134.","journal-title":"J Urol"},{"key":"841_CR6","doi-asserted-by":"crossref","first-page":"566","DOI":"10.7326\/0003-4819-132-7-200004040-00009","volume":"132","author":"J Seidenfeld","year":"2000","unstructured":"Seidenfeld J, Samson DJ, Hasselblad V, Aronson N, Albertsen PC, Bennett CL, et al. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis. Ann Intern Med. 2000;132:566\u201377.","journal-title":"Ann Intern Med"},{"key":"841_CR7","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. The Lancet Oncology. 2012;13:983\u201392.","journal-title":"The Lancet Oncology"},{"key":"841_CR8","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","volume":"377","author":"K Fizazi","year":"2017","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer. N Engl J Med. 2017;377:352\u201360.","journal-title":"N Engl J Med"},{"key":"841_CR9","first-page":"1","volume":"14","author":"H Lepor","year":"2012","unstructured":"Lepor H, Shore ND. LHRH agonists for the treatment of prostate cancer: 2012. Reviews in urology. 2012;14:1\u201312.","journal-title":"Reviews in urology"},{"key":"841_CR10","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1016\/j.eururo.2017.06.036","volume":"72","author":"FB Thomsen","year":"2017","unstructured":"Thomsen FB, Sandin F, Garmo H, Lissbrant IF, Ahlgren G, van Hemelrijck M, et al. Gonadotropin-releasing hormone agonists, orchiectomy, and risk of cardiovascular disease: semi-ecologic, nationwide, population-based study. Eur Urol. 2017;72:920\u20138.","journal-title":"Eur Urol"},{"key":"841_CR11","doi-asserted-by":"crossref","first-page":"e107516","DOI":"10.1371\/journal.pone.0107516","volume":"9","author":"J Zhao","year":"2014","unstructured":"Zhao J, Zhu S, Sun L, Meng F, Zhao L, Zhao Y, et al. Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies. PLoS One. 2014;9:e107516.","journal-title":"PLoS One"},{"key":"841_CR12","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.eururo.2014.11.039","volume":"68","author":"C Bosco","year":"2015","unstructured":"Bosco C, Bosnyak Z, Malmberg A, Adolfsson J, Keating NL, Van Hemelrijck M. Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis. Eur Urol. 2015;68:386\u201396.","journal-title":"Eur Urol"},{"key":"841_CR13","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","volume":"306","author":"PL Nguyen","year":"2011","unstructured":"Nguyen PL, Je Y, Schutz FA, et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials. Jama. 2011;306:2359\u201366.","journal-title":"Jama"},{"key":"841_CR14","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.eururo.2012.01.045","volume":"61","author":"JC Hu","year":"2012","unstructured":"Hu JC, Williams SB, O\u2019Malley AJ, Smith MR, Nguyen PL, Keating NL. Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism. Eur Urol. 2012;61:1119\u201328.","journal-title":"Eur Urol"},{"key":"841_CR15","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S1470-2045(10)70038-3","volume":"11","author":"M Van Hemelrijck","year":"2010","unstructured":"Van Hemelrijck M, Adolfsson J, Garmo H, et al. Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden. The Lancet Oncology. 2010;11:450\u20138.","journal-title":"The Lancet Oncology"},{"key":"841_CR16","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1016\/j.juro.2011.07.035","volume":"186","author":"MR Smith","year":"2011","unstructured":"Smith MR, Klotz L, van der Meulen E, Colli E, Tanko LB. Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix. J Urol. 2011;186:1835\u201342.","journal-title":"J Urol"},{"key":"841_CR17","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1111\/j.1464-410X.2008.08183.x","volume":"102","author":"L Klotz","year":"2008","unstructured":"Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson BE, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102:1531\u20138.","journal-title":"BJU Int"},{"key":"841_CR18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","volume":"65","author":"PC Albertsen","year":"2014","unstructured":"Albertsen PC, Klotz L, Tombal B, Grady J, Olesen TK, Nilsson J. Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist. Eur Urol. 2014;65:565\u201373 Trial showing fewer CVD events in patients with pre-existing CVD who received an antagonist instead of an agonist. This study may change selection of cancer therapy protocols in patients with prostate cancer and CVD.","journal-title":"Eur Urol"},{"key":"841_CR19","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1097\/COC.0b013e318201a406","volume":"35","author":"A Collier","year":"2012","unstructured":"Collier A, Ghosh S, McGlynn B, Hollins G. Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review. Am J Clin Oncol. 2012;35:504\u20139.","journal-title":"Am J Clin Oncol"},{"key":"841_CR20","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.urology.2003.10.063","volume":"63","author":"MR Smith","year":"2004","unstructured":"Smith MR. Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer. Urology. 2004;63:742\u20135.","journal-title":"Urology"},{"key":"841_CR21","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.urolonc.2014.06.018","volume":"32","author":"SN Hopmans","year":"2014","unstructured":"Hopmans SN, Duivenvoorden WC, Werstuck GH, Klotz L, Pinthus JH. GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model. Urol Oncol. 2014;32:1126\u201334.","journal-title":"Urol Oncol"},{"key":"841_CR22","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/acel.12331","volume":"14","author":"XM Liu","year":"2015","unstructured":"Liu XM, Chan HC, Ding GL, Cai J, Song Y, Wang TT, et al. FSH regulates fat accumulation and redistribution in aging through the Galphai\/Ca(2+)\/CREB pathway. Aging Cell. 2015;14:409\u201320.","journal-title":"Aging Cell"},{"key":"841_CR23","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1016\/j.urolonc.2017.01.025","volume":"35","author":"ED Crawford","year":"2017","unstructured":"Crawford ED, Schally AV, Pinthus JH, Block NL, Rick FG, Garnick MB, et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. Urol Oncol. 2017;35:183\u201391.","journal-title":"Urol Oncol"},{"key":"841_CR24","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMra043430","volume":"352","author":"GK Hansson","year":"2005","unstructured":"Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685\u201395.","journal-title":"N Engl J Med"},{"key":"841_CR25","doi-asserted-by":"crossref","first-page":"26220","DOI":"10.1038\/srep26220","volume":"6","author":"A Knutsson","year":"2016","unstructured":"Knutsson A, Hsiung S, Celik S, Rattik S, Mattisson IY, Wigren M, et al. Treatment with a GnRH receptor agonist, but not the GnRH receptor antagonist degarelix, induces atherosclerotic plaque instability in ApoE(\u2212\/\u2212) mice. Sci Rep. 2016;6:26220.","journal-title":"Sci Rep"},{"key":"841_CR26","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.2165\/11594540-000000000-00000","volume":"34","author":"E Martin-Merino","year":"2011","unstructured":"Martin-Merino E, Johansson S, Morris T, Garcia Rodriguez LA. Androgen deprivation therapy and the risk of coronary heart disease and heart failure in patients with prostate cancer: a nested case-control study in UK primary care. Drug Saf. 2011;34:1061\u201377.","journal-title":"Drug Saf"},{"key":"841_CR27","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","volume":"367","author":"HI Scher","year":"2012","unstructured":"Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367:1187\u201397.","journal-title":"N Engl J Med"},{"key":"841_CR28","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S1470-2045(15)70113-0","volume":"16","author":"Y Loriot","year":"2015","unstructured":"Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16:509\u201321.","journal-title":"Lancet Oncol"},{"key":"841_CR29","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368:138\u201348.","journal-title":"N Engl J Med"},{"key":"841_CR30","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377:338\u201351 Trial shows favorable outcomes with the addition of a novel drug with minimal CVD side effects.","journal-title":"N Engl J Med"},{"key":"841_CR31","doi-asserted-by":"crossref","first-page":"13","DOI":"10.2147\/DDDT.S15850","volume":"6","author":"Y Rehman","year":"2012","unstructured":"Rehman Y, Rosenberg JE. Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer. Drug design, development and therapy. 2012;6:13\u20138.","journal-title":"Drug design, development and therapy"},{"key":"841_CR32","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","volume":"90","author":"A O\u2019Donnell","year":"2004","unstructured":"O\u2019Donnell A, Judson I, Dowsett M, Raynaud F, Dearnaley D, Mason M, et al. Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer. Br J Cancer. 2004;90:2317\u201325.","journal-title":"Br J Cancer"},{"key":"841_CR33","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/1758834016656493","volume":"8","author":"E Verzoni","year":"2016","unstructured":"Verzoni E, Grassi P, Ratta R, Niger M, de Braud F, Valdagni R, et al. Safety of long-term exposure to abiraterone acetate in patients with castration-resistant prostate cancer and concomitant cardiovascular risk factors. Therapeutic advances in medical oncology. 2016;8:323\u201330.","journal-title":"Therapeutic advances in medical oncology"},{"key":"841_CR34","doi-asserted-by":"crossref","first-page":"e16534","DOI":"10.1200\/JCO.2016.34.15_suppl.e16534","volume":"34","author":"V Prati","year":"2016","unstructured":"Prati V, Ruatta F, Gernone A, Aversa C, Galizia D, Torino S, et al. Prospective evaluation of the cardiovascular safety profile of abiraterone acetate (AA) in mCRPC patients (pts). J Clin Oncol. 2016;34:e16534.","journal-title":"J Clin Oncol"},{"key":"841_CR35","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1089\/jwh.2011.3444","volume":"21","author":"T Sedlak","year":"2012","unstructured":"Sedlak T, Shufelt C, Iribarren C, Merz CN. Sex hormones and the QT interval: a review. J Women\u2019s Health. 2012;21:933\u201341.","journal-title":"J Women\u2019s Health"},{"key":"841_CR36","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.1200\/jco.2004.22.90140.4578","volume":"22","author":"MB Garnick","year":"2004","unstructured":"Garnick MB, Pratt CM, Campion M, Shipley J. The effect of hormonal therapy for prostate cancer on the electrocardiographic QT interval: phase 3 results following treatment with leuprolide and goserelin, alone or with bicalutamide, and the GnRH antagonist abarelix. J Clin Oncol. 2004;22:4578.","journal-title":"J Clin Oncol"},{"key":"841_CR37","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1161\/CIRCULATIONAHA.109.192695","volume":"121","author":"GN Levine","year":"2010","unstructured":"Levine GN, D\u2019Amico AV, Berger P, Clark PE, Eckel RH, Keating NL, et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation. 2010;121:833\u201340.","journal-title":"Circulation"},{"key":"841_CR38","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","volume":"133","author":"N Bhatia","year":"2016","unstructured":"Bhatia N, Santos M, Jones LW, Beckman JA, Penson DF, Morgans AK, et al. Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer. Circulation. 2016;133:537\u201341.","journal-title":"Circulation"},{"key":"841_CR39","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10552-011-9881-x","volume":"23","author":"\u00daC Mc Menamin","year":"2012","unstructured":"Mc Menamin \u00daC, Murray LJ, Cantwell MM, Hughes CM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cancer progression and survival: a systematic review. Cancer Causes Control. 2012;23:221\u201330.","journal-title":"Cancer Causes Control"},{"key":"841_CR40","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2013.11.033","volume":"65","author":"MR Harrison","year":"2014","unstructured":"Harrison MR, Jones LW. Exercise as treatment for androgen deprivation therapy-associated physical dysfunction: ready for prime time? Eur Urol. 2014;65:873\u20134.","journal-title":"Eur Urol"},{"key":"841_CR41","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1200\/JCO.2013.54.8875","volume":"32","author":"EJ Jacobs","year":"2014","unstructured":"Jacobs EJ, Newton CC, Stevens VL, Campbell PT, Freedland SJ, Gapstur SM. Daily aspirin use and prostate cancer-specific mortality in a large cohort of men with nonmetastatic prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2014;32:3716\u201322 Study highlights benefits of aspirin for the prostate cancer population.","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"}],"container-title":["Current Oncology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11912-019-0841-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11912-019-0841-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T23:31:09Z","timestamp":1598139069000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11912-019-0841-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["841"],"URL":"https:\/\/doi.org\/10.1007\/s11912-019-0841-z","relation":{},"ISSN":["1523-3790","1534-6269"],"issn-type":[{"value":"1523-3790","type":"print"},{"value":"1534-6269","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"assertion":[{"value":"24 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"Megha Agarwal, Timothy Canan, Greg Glover, Nidhi Thareja, Andre Akhondi, and Joshua Rosenberg declare they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}],"article-number":"91"}}